2025年4月26日 周六
首页 > 按月查看>2018年第12月 >1291-1296
PDF 导出
ApoCⅢ与动脉粥样硬化性心血管疾病相关性的研究进展
作者:
作者单位:

(1.山西医科大学,山西省太原市 030000;2.山西医科大学第二医院心内科,山西省太原市030000)

作者简介:

陈瑞瑞,硕士研究生,研究方向为脂蛋白代谢异常与动脉粥样硬化,E-mail为1285750620@qq.com。通信作者周华,博士,副主任医师,副教授,硕士研究生导师,主要研究方向为脂蛋白代谢异常与动脉粥样硬化,E-mail为zhouhua032670@sina.com。


Research progress of the relationship between ApoCⅢ and atherosclerosis cardiovascular diseases
Author:
Affiliation:

1.Shanxi Medical University, Taiyuan, Shanxi 030000, China;2.Department of Cardiology, the Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030000, China)

  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献
    • |
  • 相似文献
    • |
  • 引证文献
    • |
    摘要:

    载脂蛋白CⅢ (ApoCⅢ)不仅通过脂代谢紊乱参与动脉粥样硬化(As)等心血管疾病的发生、发展,近年来还作为一个独立的促炎和致As角色被重新认识,不仅临床研究发现ApoCⅢ与心血管疾病相关,其与心血管疾病的相关细胞效应也在基础研究中得到证实。值得庆幸的是,除了传统治疗策略,如生活方式的改变和降脂药物治疗,专门针对ApoCⅢ-mRNA的反义寡核苷酸药物(ASO)开启了降低ApoCⅢ及心血管疾病治疗的新时代。文章就有关ApoCⅢ的临床意义及未来治疗方向进行以下综述。

    Abstract:

    Apolipoprotein CⅢ (ApoCⅢ) not only participates in the occurrence and development of atherosclerosis cardiovascular diseases(ASCVD) through lipid metabolism disorders, but also has been recognized as an independent factor of inflammatory and atherosclerosis. Clinical studies have found that ApoCⅢ was linked with cardiovascular disease(CVD), and its cellular effects related with CVD are also confirmed in basic research. Fortunately, in addition to traditional therapeutic strategies, such as lifestyle changes and lipid-lowering drug treatments, antisense oligonucleotides specifically targeting ApoCⅢ mRNA have opened the door to a new era of reducing ApoCⅢ and the treatment of CVD. Therefore, this paper summarizes the clinical significance of ApoCⅢ and the future treatment direction.

    参考文献
    [1] Li H, Han Y, Qi R, et al.Aggravated restenosis and atherogenesis in ApoCⅢ transgenic mice but lack of protection in ApoCⅢ knockouts:the effect of authentic triglyceride-rich lipoproteins with and without ApoCⅢ .Cardiovasc Res, 5,7(4):579-589.
    [2] Jensen MK, Aroner SA, Mukamal KJ, et al.HDL subspecies defined by presence of apolipoprotein C-Ⅲ and incident coronary heart disease in four cohorts .Circulation, 7,5.
    [3] Jrgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al.Loss-of-function mutations in APOC3 and risk of ischemic vascular disease .N Engl J Med, 4,1(1):32-41.
    [4] Zheng C, Azcutia V, Aikawa E, et al.Statins suppress apolipoprotein CⅢ-induced vascular endothelial cell activation and monocyte adhesion .Eur Heart J, 3,4(8):615-624.
    [5] vall K, Ali Y, Leibiger IB, et al.Apolipoprotein CⅢ links islet insulin resistance to β-cell failure in diabetes .Proc Natl Acad Sci U S A, 5,2(20):E2611-2619.
    [6] Norata GD, Tsimikas S, Pirillo A, et al.Apolipoprotein C-Ⅲ:from pathophysiology to pharmacology .Trends Pharmacol Sci, 5,6(10):675-687.
    [7] Ooi E M, Barrett P H, Chart D C, et al.Apolipoprotein C-Ⅲ:understanding an emergingcardiovascular risk factor .Clin Sci(Lond), 8,4(1O):611-624.
    [8] Altomonte J, Cong L, Harbaran S, et al.Foxo1 mediates insulin action on apoC-Ⅲ and triglyceride metabolism .J Clin Invest, 4,4(10):1493-1503.
    [9] Caron S, Verrijken A, Mertens I, et al.Transcriptional activation of apolipoprotein CⅢ expression by glucose may contribute to diabetic dyslipidemia .Arterioscler Thromb Vasc Biol, 1,1:513-519.
    [10] Hertz R, Bishara-Shieban J, Bar-Tana J.Mode of action of peroxisome proliferators as hypolipidemic drugs.Suppression of apolipoprotein C-Ⅲ.J Biol Chem, 5,0(22):13470-13475.
    [11] Claudel T, Inoue Y, Barbier O, et al.Farnesoid X receptor agonists suppress hepatic apolipoprotein CⅢ expression .Gastroenterology, 3,5(2):544-555.
    [12] Ito Y, Azrolan N, O'Connell A, et al.Hypertriglyceridemia as a result of human apo CⅢ gene expression in transgenic mice .Science, 0,9(4970):790-793.
    [13] Maeda N, Li H, Lee D, et al.Targeted disruption of the apolipoprotein C-Ⅲ gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia .J Biol Chem, 4,9(38):23610-23616.
    [14] Kavo AE, Rallidis LS, Sakellaropoulos GC, et al.Qualitative characteristics of HDL in young patients of an acute myocardial infarction .Atherosclerosis, 2,0:257-264.
    [15] Knowlton N, Wages JA, Centola MB, et al.Apolipoprotein B-containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis .Arthritis Care Res (Hoboken), 2,4:993-1000.
    [16] Lin B, Huang Y, Zhang M, et al.Association between apolipoprotein C3 Sst I, T-455C, C-482T and C1100T polymorphisms and risk of coronary heart disease .BMJ Open, 4,4(1):e004156.
    [17] Crosby J, Peloso GM, Auer PL, et al.Loss-of-function mutations in APOC3, triglycerides, and coronary disease .N Engl J Med, 4,1:22-31.
    [18] Zilversmit DB.Atherogenesis:a postprandial phenomenon .Circulation, 9,0:473-485.
    [19] Langsted A, Freiberg JJ, Tybjaerg-Hansen A, et al.Nonfasting cholesterol and triglycerides andassociation with risk of myocardial infarction and total mortality:the Copenhagen City Heart Study with 31 years of follow-up .J Intern Med, 1,0:65-75.
    [20] ACCORD Study Group, Ginsberg HN, Elam MB, et al.Effects of combination lipid therapy in type 2 diabetes mellitus .N Engl J Med, 0,2:1563-1574.
    [21] Larsson M, Vorrsj E, Talmud P, et al.Apolipoproteins C-I and C-Ⅲ inhibitlipoprotein lipase activity by displacement of the enzyme from lipid droplets .J Biol Chem, 3,8:3399.
    [22] Sundaram M, Zhong S, Bou Khalil M, et al.Expression of apolipoprotein C-Ⅲ in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions .J Lipid Res, 0,1:150-161.
    [23] Yang X, Lee S-R, Choi Y-S, et al.Reduction in lipoprotein-associated apoC-Ⅲ levels following volanesorsen therapy:phase 2 randomized trial results .J Lipid Res, 6,7(4):706-713.
    [24] Gordts PL, Nock R, Son NH, et al.ApoC-Ⅲ inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors .J Clin Invest, 6,6(8):2855-2866.
    [25] Rosenson RS, Brewer Jr HB, Ansell B, et al.Translation of high- density lipoprotein function into clinical practice:current prospects and future challenges .Circulation, 3,8:1256-1267.
    [26] Xiong X, Liu H, Hua L, et al.The association of HDL-apoCⅢ with coronary heartdisease and the effect of statin treatment on it .Lipids Health Dis, 5,4:127.
    [27] Riwanto M, Rohrer L, Roschitzki B, et al.Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary disease:role of high-density lipoprotein-proteome remodeling .Circulation, 3,7(8):891-904.
    [28] Holzer M, Birner-Gruenberger R, Stojakovic T, et al.Uremia alters HDL composition and function .J Am Soc Nephrol, 1,2:1631-1641.
    [29] Luo M, Liu A, Wang S, et al.ApoCⅢ enrichment in HDL impairs HDL-mediated cholesterol efflux capacity .Sci Rep, 7,7(1):2312.
    [30] Yamamoto R, Sacks FM, Hu FB, et al.High density lipoprotein with apolipoprotein C-Ⅲ is associated with carotid intima-media thickness among generally healthy individuals .Atherosclerosis, 8,9:92-99.
    [31] Chang PY, Lee CM, Hsu HC, et al.Identification of the HDL-ApoCⅢ to VLDL-ApoCⅢ ratio as a predictor of coronary artery disease in the general population:The Chin-Shan Community Cardiovascular Cohort (CCCC) study in Taiwan .Lipids Health Dis, 2,1:162.
    [32] Jensen MK, Aroner SA, Mukamal KJ, et al.HDL subspecies defined by presence of apolipoprotein C-Ⅲ and incident coronary heart disease in four cohorts .Circulation, 8,7:1364-1373.
    [33] Kawakami A, Aikawa M, Nitta N, et al.Apolipoprotein CⅢ-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive g proteinand protein kinase c-mediated nuclear factor-κB activation .Arterioscler Thromb Vasc Biol, 7,7:219-225.
    [34] Kawakami A, Aikawa M, Alcaide P, et al.Apolipoprotein CⅢ induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells .Circulation, 6,4:681-687.
    [35] Zheng C, Azcutia V, Aikawa E, et al.Statins suppress apolipoprotein CⅢ-induced vascular endothelial cell activation and monocyte adhesion .Eur Heart J, 3,4:615-624.
    [36] Kawakami A, Yoshida M.Apolipoprotein CⅢ links dyslipidemia with atherosclerosis .J Atheroscler Thromb, 9,6(1):6-11.
    [37] Kawakami Akio, Osaka Mizuko, Tani Mariko, et al.Apolipoprotein CⅢ links hyperlipidemia with vascular endothelial cell dysfunction .Circulation, 8,8(7):731-742.
    [38] Olivieri O, Martinelli N, Girelli D, et al.Apolipoprotein C-Ⅲ predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation .J Thromb Haemost, 0,8:463-471.
    [39] Olivieri O, Martinelli N, Baroni M, et al.Factor II activity is similarly increased in patients with elevated apolipoprotein CⅢ and in carriers of the factor Ⅱ 20210A allele .J Am Heart Assoc, 3,2(6):e000440.
    [40] Tao Y, Xiong Y, Wang H, et al.APOC3 induces endothelial dysfunction through TNF-α and JAM-1 .Lipids Health Dis, 6,5(1):153.
    [41] Han X, Wang T, Zhang J, et al.Apolipoprotein CⅢ regulates lipoprotein-associated phospholipase A2 expression via the MAPK and NFκB pathways .Biology Open, 5,4(5):661-665.
    [42] Fernandez ML, Metghalchi S, Vega-López S, et al.Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women .J Nutr Biochem, 4,5(12):717-721.
    [43] Shin MJ, Blanche PJ, Rawlings RS, et al.Increased plasma concentrations of lipoprotein(a) during a low-fat, high-carbohydrate diet are associated with increased plasma concentrations of apolipoprotein C-Ⅲ bound to apolipoprotein B-containing lipoproteins .Am J Clin Nutr, 7,5(6):1527-1532.
    [44] Morton AM, Furtado JD, Lee J, et al.The effect ofomega-3 carboxylic acids on apolipoprotein CⅢ containing lipoproteins in severe hypertriglyceridemia .J Clin Lipidol, 6,0(6):1442-1451.
    [45] Soccio RE, Chen ER, Rajapurkar SR, et al.Genetic variation determines PPARγ function and antidiabetic drug response in vivo .Cell, 5,2(1):33-44.
    [46] Schuster H, Fagerberg B, Edwards S, et al.Tesaglitazar, a dual peroxisome proliferatoractivated receptor α/γ agonist, improves apolipoprotein levels innon-diabetic subjects with insulin resistance .Atherosclerosis, 8,7:355-362.
    [47] Ooi EMM, Watts GF, Chan DC, et al.Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-Ⅲ kinetics in the metabolic syndrome .Diabetes Care, 8,1(8):1656-1661.
    [48] Khetarpal SA, Zeng X, Millar JS, et al.A human APOC3 missense variant and monoclonal antibody accelerate apoC-Ⅲ clearance and lower triglyceride-rich lipoprotein levels.Nature Med, 7,3(9):1086-1094.
    [49] Graham MJ, Lee RG, Bell TA , et al.Antisense oligonucleotide inhibition of apolipoprotein C-Ⅲ reduces plasma triglycerides in rodents, nonhuman primates, and humans .Circ Res, 3,2:1479-1490.
    [50] Yang X, Lee SR, Choi YS, et al.Reduction in lipoprotein-associated apoC-Ⅲ levels following volanesorsen therapy:phase 2 randomized trial results .J Lipid Res, 6,7:706-713.
    [51] IoannaG-B, Veronica A, Andres D et al.Apolipoprotein C-Ⅲ inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS):a randomized, double-blind, placebo-controlled trial .J Clin Lipidol, 7,1(3):794-795.
    [52] Gaudet D, Digenio A, Alexander VJ, et al.The APPROACH study:a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS) .J Clin Lipidol, 7,1:814-815.
    相似文献
    引证文献
引用本文

陈瑞瑞,周华. ApoCⅢ与动脉粥样硬化性心血管疾病相关性的研究进展[J].中国动脉硬化杂志,2018,26(12):1291~1296.

复制
分享
文章指标
  • 点击次数:887
  • 下载次数: 773
历史
  • 收稿日期:2018-03-19
  • 最后修改日期:2018-05-12
  • 在线发布日期: 2018-12-27

您是本站第 访问者

邮编：421001 传真：0734-8160523

电话：0734-8160765 E-mail：dmzzbjb@163.net

中国动脉硬化杂志 ® 2025 网站版权所有